Form DEFA14A Spyre Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'
April 13, 2026 8:21 AM EDTLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).
The analyst comments "SYRE (OP) announced positive topline results from the open-label SPY001 (anti-47) monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC). Importantly, SPY001 demonstrated class-leading efficacy on the study's primary and key secondary endpoints, showing an impressive -9.2pt reduction from baseline on the primary RHI endpoint and a 40% clinical remission rate at week 12 - both data points suggesting differentiated efficacy relative to TAK's (NR)... More
Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'
April 13, 2026 7:46 AM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $115.00 price target on Spyre (NASDAQ: SYRE).
The analyst comments "Spyre announced topline results for SPY001's monotherapy study in SKYLINE-UC Part A (n~130). Across multiple endpoints (RHI from baseline, clinical remission, endoscopic improvement), SPY001/47 consistently outperformed TAK's Entyvio (both Week 6 & 14 comps), with most notable efficacy outcome of 40% clinical remission at week 12 (Fig 1 & 2). The induction CR data is one of the highest we have seen and significantly... More
